To investigate the clinical impact of EZH2 on breast cancer progression, we used UALCAN and the Kaplan-Meier plotter to assess the relationship between cellular levels of EZH2 mRNA and different types of breast cancer patient outcomes. Here, EZH2 is linked to breast carcinoma.